Brand, D. H., Tree, A. C., Ostler, P., van der Voet, H., Loblaw, A., Chu, W., Ford, D., Tolan, S., Jain, S., Martin, A., Staffurth, J., Camilleri, P., Kancherla, K., Frew, J., Chan, A., Dayes, I. S., Henderson, D., Brown, S., Cruickshank, C., Burnett, S., Duffton, A., Griffin, C., Hinder, V., Morrison, K., Naismith, O., Hall, E., van As, N., , , Dodds, D., Lartigau, E., Patton, S., Thompson, A., Winkler, M., Wells, P., Lymberiou, T., Saunders, D., Vilarino-Varela, M., Vavassis, P., Tsakiridis, T., Carlson, R., Rodrigues, G., Tanguay, J., Iqbal, S., Winkler, M., Morgan, S., Mihai, A., Li, A., Din, O., Panades, M., Wade, R., Rimmer, Y., Armstrong, J., Panades, M., & Oommen, N. (2019). intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet oncology, 20(11), 1531–1543. http://access.bl.uk/ark:/81055/vdc_100141198236.0x000016